Skip to content

Clinical trials

Observational Muscle Weakness trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Muscle Weakness Phase: Observational Clear all

106 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20021
20041
20052
20072
20081
20123
20133
20143
20153
20161
20179
201812
20193
20206
202112
20227
202315
20249
20256
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed62
Recruiting14
Unknown status13
Active, not recruiting7
Terminated5
Not yet recruiting3
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Bezmialem Vakif University3
CENTOGENE GmbH Rostock3
Massachusetts General Hospital3
University Hospital, Caen3
Vanderbilt University Medical Center3
Cairo University2
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2
Fatih Sultan Mehmet Training and Research Hospital2
Hacettepe University2
Insel Gruppe AG, University Hospital Bern2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Muscle Weakness106
Critical Illness14
Sarcopenia13
Muscular Diseases8
Muscular Atrophy7
Frailty6
Neuromuscular Diseases5
Anterior Cruciate Ligament Injuries4
Deglutition Disorders3
Fatigue3

Trials

Showing 26 to 50 of 106. Each trial links to its page on Pharma Observatory.

6 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.